广州神桥生物科技有限公司成立于2023年9月,是一家专注非人灵长类动物 (NHP)精准基因编辑疾病模型开发应用与转化的平台。
Founded in September 2023, Guangzhou NeuroBridge Biotechnology Co., Ltd. is a platform dedicated to the development, application and transformation of precision gene-edited disease models for non-human primates (NHPs).
深耕非人灵长类基因编辑领域,以猴等非人灵长类动物为核心载体,链接科研与临床需求,用精准模型搭建生命健康的探索之桥,用专业服务赋能医学创新突破。
Deeply engaged in the field of non-human primate gene editing, we take monkeys and other non-human primates as the core carrier, connect scientific research and clinical needs, build a bridge for exploring life and health with precise models, and empower medical innovation breakthroughs with professional services.
源于对生命的敬与对医学困境的深切感知,立志打破灵长类基因编辑模型领域的技术壁垒与应用瓶颈。以"让科研更高效、让诊疗有突破"为初心,打造一站式服务平台,为无数受疾病困扰的家庭带去希望。
Rooted in respect for life and deep understanding of medical dilemmas, we aim to break the technical barriers and application bottlenecks in the field of primate gene-edited models. With the original aspiration of "Making scientific research more efficient and enabling breakthroughs in diagnosis and treatment", we build a one-stop service platform to bring hope to countless families affected by diseases.
聚焦基因编辑猴模型的研发、制备与全链条服务,搭建科研与临床的桥梁,赋能医学创新,守护人类健康。提供标准化、定制化的基因编辑猴模型及配套技术服务,加速科研成果向临床应用转化。
Focus on the R&D, preparation and full-chain services of gene-edited monkey models, build a bridge between scientific research and clinical practice, empower medical innovation, and protect human health. Provide standardized and customized gene-edited monkey models and supporting technical services to accelerate the transformation of scientific research achievements into clinical applications.
成为全球灵长类基因编辑模型领域的引领者与最受信赖的合作伙伴,助力人类攻克重大疾病难题,最终实现"尝尽世间药,只为人健康"的美好愿景。
To become a global leader and the most trusted partner in the field of primate gene-edited models, help humanity overcome major disease challenges, and ultimately realize the beautiful vision of "All For Your Health".
提高模型猴利用率,整合科研资源,全面立体研究疾病进程机体变化
Improve model monkey utilization, integrate scientific research resources, and comprehensively study the body changes during disease progression
为高校、医院等提供成规模模型,促进基础科研突破,赋能原始创新
Provide large-scale models for universities and hospitals, promote basic scientific research breakthroughs, and empower original innovation
为药企、CRO等精准做临床前药物评价,结合先进技术提高评估准确性,促进新药上市
Provide accurate preclinical drug evaluation for pharmaceutical companies and CROs, improve evaluation accuracy with advanced technologies, and promote new drug launch